Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
BeOne Medicines
MOMA Therapeutics
Eli Lilly and Company
Masaryk Memorial Cancer Institute
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
The New York Proton Center
Nammi Therapeutics Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Jazz Pharmaceuticals
Fred Hutchinson Cancer Center
Bayer
Memorial Sloan Kettering Cancer Center
Conjupro Biotherapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Wake Forest University Health Sciences
Actuate Therapeutics Inc.
Conjupro Biotherapeutics, Inc.
NRG Oncology
Memorial Sloan Kettering Cancer Center
Astellas Pharma Inc
858 Therapeutics, Inc.
Institut de Cancérologie de Lorraine
City of Hope Medical Center
GlaxoSmithKline
SystImmune Inc.
Orano Med LLC
University of Southern California
Filamon LTD
Atavistik Bio, Inc
PMV Pharmaceuticals, Inc
AstraZeneca
Roswell Park Cancer Institute
OHSU Knight Cancer Institute
University of Michigan Rogel Cancer Center
Alterome Therapeutics, Inc.
Hoffmann-La Roche
Rutgers, The State University of New Jersey
Monte Rosa Therapeutics, Inc
Psyence Australia Pty Ltd
ViroMissile, Inc.
University of Virginia
Dana-Farber Cancer Institute
Kaiser Permanente